Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.
about
Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activityIdentification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance proteinMechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastasesIn vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.Development of conformation independent computational models for the early recognition of breast cancer resistance protein substrates.Overlapping substrate and inhibitor specificity of human and murine ABCG2.Drug transport by breast cancer resistance protein.The effects of flavonoids on the ABC transporters: consequences for the pharmacokinetics of substrate drugs.Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.Transporter assays as useful in vitro tools in drug discovery and development.ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activatedThe effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo.PharmGKB summary: very important pharmacogene information for ABCG2.Protective mechanisms of resveratrol against methotrexate-induced renal damage may involve BCRP/ABCG2.In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin.
P2860
Q28083142-6B5DF63D-E40E-44AD-A45C-6F515ECABD27Q33506860-FF37F34B-C65C-417B-BC74-8C2136014988Q33566582-0B0E9B31-0C97-4447-B7DE-9181AFC817B4Q34124847-23D3ACBF-404B-49DC-9E0C-DA2AC14DAE7CQ34458602-6F1D3F2E-6E00-4578-8FDE-E0201917EAE5Q34871636-A4010D0C-9FED-4EA3-A38C-627B44C2AD67Q35033091-5F4B83F3-D5C7-4B72-BFA0-C693E21A6498Q36642420-F1C33973-E0F8-4574-A821-F7AA0003A9A3Q37070476-C781E4DE-67AA-4A18-A878-10E46DE4D42EQ37105057-4494E0CC-E3B7-4C97-AD57-0F2E0DA29ADFQ37193073-7BAA290F-66B5-48BF-90CD-41512FC81134Q37793056-D58A7104-5F67-4825-A6D5-D36F81AEF0BFQ38071690-FEB5358A-78F5-4224-917C-AC6877D83FBBQ38099195-0743F7A2-32D7-430A-A806-EA7835B687EAQ38619057-500F1B81-BD33-4163-B5B1-25181DCA3AAFQ38887917-A18D638D-9351-4918-9B21-C3A1A997A771Q39341824-89FF5703-89B6-425C-9B2E-C95406A37A0AQ39675232-46D2C7DA-E071-4ADF-99C5-A3CAC8FB687EQ42711587-1C4D9527-DC6E-44CD-B30E-CA6A69EC3597Q43003337-05CFA413-6512-4ED2-A57C-ACA1BB916613Q46018199-8C0C7E5E-71D0-4286-BA8A-D41B34BCB740Q46502320-35B640D5-8526-404D-B328-01A86EE5363AQ47819133-4CD79BE6-530B-452A-A0A4-2B2467E75043Q52710300-822EFFBD-3258-400B-BECE-6B52C5760935
P2860
Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Substrate-dependent breast can ...... ites in in vitro assay design.
@en
Substrate-dependent breast cancer resistance protein
@nl
type
label
Substrate-dependent breast can ...... ites in in vitro assay design.
@en
Substrate-dependent breast cancer resistance protein
@nl
prefLabel
Substrate-dependent breast can ...... ites in in vitro assay design.
@en
Substrate-dependent breast cancer resistance protein
@nl
P2093
P2860
P356
P1476
Substrate-dependent breast can ...... ites in in vitro assay design.
@en
P2093
Nagdeep Giri
Naveed Shaik
Sagar Agarwal
William F Elmquist
P2860
P304
P356
10.1124/DMD.108.022046
P577
2008-12-04T00:00:00Z